跳转至内容
Merck
CN

Y0000378

丝裂霉素

European Pharmacopoeia (EP) Reference Standard

别名:

丝裂霉素 C

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C15H18N4O5
化学文摘社编号:
分子量:
334.33
UNSPSC Code:
41116107
EC Number:
200-008-6
NACRES:
NA.24
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

SMILES string

N21[C@]([C@H]4N[C@H]4C2)([C@@H](C3=C1C(=O)C(=C(C3=O)N)C)COC(=O)N)OC

InChI key

NWIBSHFKIJFRCO-WUDYKRTCSA-N

InChI

1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1

grade

pharmaceutical primary standard

API family

mitomycin

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

正在寻找类似产品? 访问 产品对比指南

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Mitomycin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Skull and crossbonesHealth hazard

signalword

Danger

hcodes

Hazard Classifications

Acute Tox. 2 Oral - Carc. 2

存储类别

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

涉药品监管产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Rose K Sia et al.
Journal of refractive surgery (Thorofare, N.J. : 1995), 30(4), 256-264 (2014-04-08)
To compare visual outcomes following photorefractive keratectomy (PRK), PRK with mitomycin C (MMC-PRK), and LASEK in moderate and high myopia in military personnel. This prospective, randomized contralateral eye study included 167 patients 21 years or older with manifest spherical equivalent
Yi-fan Feng et al.
Ophthalmic epidemiology, 19(6), 364-370 (2012-11-23)
To assess the efficacy and safety of local application of intraoperative mitomycin C (MMC) at the osteotomy site in primary external dacryocystorhinostomy (EX-DCR). A comprehensive literature search of the Cochrane Library, PubMed and Embase was undertaken to identify relevant trials
Mamoun H Elmamoun et al.
BJU international, 113(5b), E34-E38 (2013-09-24)
To identify a cohort of patients under our care who have had significant and in some cases irreparable damage to their bladders after Mitomycin C (MMC) instillation. To highlight the importance of avoidance and recognition of bladder perforations during transurethral
Karan Madan et al.
Journal of bronchology & interventional pulmonology, 19(4), 304-310 (2012-12-05)
Postintubation tracheal stenosis (PITS) is a common problem encountered by interventional pulmonologists. The aim of this study was to evaluate the utility of mitomycin C (MMC) as an adjunctive treatment to rigid bronchoscopic dilatation in patients with PITS. Prospective analysis
Rebecca Kleinerman et al.
Journal of drugs in dermatology : JDD, 12(6), 701-703 (2013-07-11)
Mitomycin C (MMC) is an antineoplastic antibiotic that has been used off-label in the treatment of hypertrophic scars and keloids. Herein we report our successful use of this agent in a patient with sternal keloids refractory to other means of

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持